STOK
NASDAQStoke Therapeutics Inc.
News · 26 weeks770%
2025-12-142026-06-07
Mix5190d
- Insider25(49%)
- SEC Filings12(24%)
- Other11(22%)
- Earnings2(4%)
- Leadership1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Tzianabos Arthur4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith Julie4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Levin Arthur A4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Krainer Adrian R.4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Kaye Edward M. Md4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Harrison Seth Loring4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Director Burstein Jennifer4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SECSEC Form 8-K filed by Stoke Therapeutics Inc.8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry sold $54,891 worth of shares (1,795 units at $30.58) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 34,826 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- PRStoke Therapeutics to Present at Upcoming Investor Conferences in JuneStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 9:20 a.m. ET Location: New York, NY Goldman Sachs 47th Annual Global Healthcare Conference 2026 Date: Monday, June 8, 2026 Time: 10:40 a
- PRStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on May 15, 2026, it granted stock options to purchase an aggregate of 106,200 shares of common stock to eight new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $30.08 per share, which is equal to the closing price of Sto
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
- SECSEC Form SCHEDULE 13G filed by Stoke Therapeutics Inc.SCHEDULE 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)
- SECStoke Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
- SECSEC Form 10-Q filed by Stoke Therapeutics Inc.10-Q - Stoke Therapeutics, Inc. (0001623526) (Filer)
- PRStoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the treatment of Dravet syndrome – – Statistically significant improvements in cognition and behavior demonstrated at 1, 2, 3 and 4 years of treatment compared to OLE baseline, in addition to continued durability in seizure reductions – – Zorevunersen generally well tolerated, with some patients treated for more than 5 years – – Enrollment of approximately 150 patients into the Phase 3 EMPEROR study expected to complete in June 2026 to support a data readout in mid-2027; these data are anti
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry sold $73,548 worth of shares (2,243 units at $32.79) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 36,621 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- PRStoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial UpdatesStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Thursday, May 7, 2026, at 4:30 p.m. ET, to discuss first quarter 2026 business and financial updates. The webcast will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the call a
- SECSEC Form DEFA14A filed by Stoke Therapeutics Inc.DEFA14A - Stoke Therapeutics, Inc. (0001623526) (Filer)
- SECSEC Form DEF 14A filed by Stoke Therapeutics Inc.DEF 14A - Stoke Therapeutics, Inc. (0001623526) (Filer)
- PRStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on April 15, 2026, it granted stock options to purchase an aggregate of 129,565 shares of common stock to fourteen new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $35.54 per share, which is equal to the closing price o
- PRStoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 3:00 p.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke Therape
- PRThe Credibility Filter Wall Street Uses to Sort Biotech WinnersVANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinical data[1]. That is not a coincidence. The IQVIA Institute's latest annual report found that biopharma dealmaking is now clustering around high value science and companies with credentialed pipelines[2]. It's becoming apparent that smart money is no longer chasing press releases, it's chasing invitations. Conference stage presentations from field defining researchers, peer reviewed journal publications, and stacked regulatory designations have become the fi
STOK FAQ
7 questionsWhat does Stoke Therapeutics Inc. do?
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera...Where does STOK stock trade?
Stoke Therapeutics Inc. (STOK) is listed on NASDAQ.What sector and industry is STOK in?
Stoke Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Stoke Therapeutics Inc. go public?
Stoke Therapeutics Inc. (STOK) completed its IPO in 2019.What are analysts saying about STOK?
Stoke Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $4000.00 price target on 2026-02-24. Recent price targets range from $1800.00 to $4000.00.What companies are similar to STOK?
Notable peers in the same industry include GTHX (G1 Therapeutics Inc.), GRTX (Galera Therapeutics Inc.), MCRB (Seres Therapeutics Inc.). Compare STOK side-by-side with any of them on Quantisnow.How can I track STOK on Quantisnow?
Quantisnow aggregates Stoke Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STOK to receive live email and push alerts on every new disclosure.